Related Experiment Video
Updated: Dec 5, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Outcomes in relation to antithrombotic therapy among patients with atrial fibrillation after percutaneous coronary
Jiesuck Park1, Eue-Keun Choi1, Kyung-Do Han2
1Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Insights
For atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI), oral anticoagulant plus antiplatelet therapy (OAC±SAPT) showed better 1-year outcomes than triple therapy (TT) or antiplatelets alone (APT). This regimen reduced composite ischemic and bleeding events post-PCI.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Atrial fibrillation (AF) patients undergoing percutaneous coronary intervention (PCI) require careful antithrombotic management.
- The optimal antithrombotic strategy beyond one year post-PCI in AF patients remains an area of active investigation.
Purpose of the Study:
- To evaluate the prognostic impact of different antithrombotic regimens at one year after PCI in patients with AF.
- To compare the risks of ischemic events and bleeding complications among various antithrombotic strategies in this high-risk population.
Main Methods:
- A retrospective cohort study utilizing the Korean National Health Insurance Service database.
- Included 13,278 AF patients who underwent PCI between 2009 and 2013.
- Patients were classified into three groups at 1-year post-PCI: OAC with or without single antiplatelet (OAC±SAPT), triple therapy (TT), and antiplatelets only (APT). Propensity score matching was employed for comparison.
Main Results:
- Compared to OAC±SAPT, triple therapy (TT) was associated with a significantly higher risk of composite clinical outcomes (ischemia and bleeding).
- The antiplatelets only (APT) group demonstrated a higher risk of ischemic events but a lower risk of bleeding events compared to the OAC±SAPT group.
- Oral anticoagulant plus single antiplatelet therapy (OAC±SAPT) showed a favorable balance of efficacy and safety.
Conclusions:
- Oral anticoagulant plus single antiplatelet therapy (OAC±SAPT) was associated with superior clinical outcomes compared to triple therapy (TT) or antiplatelets only (APT) beyond one year post-PCI.
- These findings suggest OAC±SAPT as a potentially preferred antithrombotic strategy for Asian patients with AF after PCI.
Backgrounds:
We investigated the prognostic impact of antithrombotic regimens at 1-year after percutaneous coronary intervention (PCI) among patients with atrial fibrillation (AF).
Method And Results:
A total of 13,278 AF patients who underwent PCI from 2009 to 2013 were selected from Korean National Health Insurance Service database. Patients were categorized by antithrombotic regimens at 1-year after PCI: (1) OAC with or without single antiplatelet (OAC±SAPT); (2) triple therapy (TT) and (3) antiplatelets (APT) only. After propensity score matching, composite ischaemia (death, myocardial infarction, and stroke), composite bleeding (intracranial hemorrhage and gastrointestinal bleeding), and a composite clinical outcome (composite ischaemia and bleeding) were compared. Of total population, 1,100 (8.3%), 746 (5.6%), and 11,432 (86.1%) were treated with OAC±SAPT, TT, and APT only, respectively. Compared to OAC±SAPT group, the TT group had significantly higher risk of the composite clinical outcome (hazard ratio [HR] 1.46, 95% confidence interval [CI] 1.00-2.13) attributed to a higher trend in both ischaemia (HR 1.63, 95% CI 0.99-2.67) and bleeding (HR 1.22, 95% CI 0.69-2.13). The APT only group showed a higher risk of ischaemia (HR 1.85, 95% CI 1.25-2.74), despite a lower risk of bleeding (HR 0.55, 95% CI 0.32-0.94) compared to OAC±SAPT group.
Conclusions:
OAC±SAPT was associated with better clinical outcomes compared to TT or APT only treatments, beyond 1-year after PCI among Asians with AF.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins

